Philippe Lopes-Fernandes
Corporate Officer/Principal chez IPSEN
Profil
Philippe Lopes-Fernandes is currently a Director at Histide AG and Bakx Therapeutics, Inc. He is also the Chief Business Officer & Executive Vice President at Ipsen SA. Additionally, he serves as an Industry Advisor at Agent Capital LLC.
Previously, he worked as the SVP & Head-Business Development at Merck KGaA.
He received his undergraduate degree from Institut Supérieur de Gestion in 1994.
Postes actifs de Philippe Lopes-Fernandes
| Sociétés | Poste | Début |
|---|---|---|
| IPSEN | Corporate Officer/Principal | 01/10/2020 |
Histide AG
 Histide AG Internet Software/ServicesTechnology Services Histide AG operates as a biotech intellectual property platform for non-mutagenic extracellular therapeutic agents. The company was founded by Omar F. Zouani , Benoît Lienard and Veronika Gocheva in 2014 and is headquartered in Schindellegi, Switzerland. | Director/Board Member | - |
Bakx Therapeutics, Inc.
 Bakx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bakx Therapeutics is a company based in DE that focuses on developing more effective and precise therapeutics that utilize the mitochondrial apoptosis pathway. The American company's proprietary codynx™ drug discovery platform integrates computational and experimental capabilities to collaborate with researchers in validated biological pathways. Bakx's leading asset, partnered with Ipsen, is focused on activating the bax protein to treat cancer and age-related diseases. Bakx Therapeutics, Inc. was co-founded by world-leading researchers in apoptosis and computationally aided drug discovery. Sree Kant has been the CEO of the company since 2020. | Director/Board Member | - |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Philippe Lopes-Fernandes
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK KGAA | Corporate Officer/Principal | - |
Formation de Philippe Lopes-Fernandes
| Institut Supérieur de Gestion | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| IPSEN | Health Technology |
| Entreprise privées | 3 |
|---|---|
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
Histide AG
Histide AG Internet Software/ServicesTechnology Services Histide AG operates as a biotech intellectual property platform for non-mutagenic extracellular therapeutic agents. The company was founded by Omar F. Zouani , Benoît Lienard and Veronika Gocheva in 2014 and is headquartered in Schindellegi, Switzerland. | Technology Services |
Bakx Therapeutics, Inc.
Bakx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bakx Therapeutics is a company based in DE that focuses on developing more effective and precise therapeutics that utilize the mitochondrial apoptosis pathway. The American company's proprietary codynx™ drug discovery platform integrates computational and experimental capabilities to collaborate with researchers in validated biological pathways. Bakx's leading asset, partnered with Ipsen, is focused on activating the bax protein to treat cancer and age-related diseases. Bakx Therapeutics, Inc. was co-founded by world-leading researchers in apoptosis and computationally aided drug discovery. Sree Kant has been the CEO of the company since 2020. | Health Technology |
